OncoMed: Cowen & Company Healthcare Conference (OncoMed) - Mar 7, 2014 - "Phase 1a study"; "N=22 (Dose levels: 0.5 to 15 mg/kg"; "Safety: Fzd8-Fc is well tolerated in refractory solid tumor patients"; "Biomarker: WNT pathway modulation"; "Efficacy: Potential early activity in 2/2 Desmoid tumor pts; RCC and pancreatic"
P1 data • Oncology
|